Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -72.28% is 79% below its 5-year average of -40.29%, near the high end of its 5-year range (-335.18%–16.28%).
16.60% below its 12-month average of -61.99%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -9.82%.
NET PROFIT MARGIN
-72.28%
NET PROFIT MARGIN AVG TTM
-61.99%
NET PROFIT MARGIN AVG 3Y
-110.54%
NET PROFIT MARGIN AVG 5Y
-40.29%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-16.60%
CURRENT VS 3Y AVG
+34.61%
CURRENT VS 5Y AVG
-79.39%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 452 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Definitive Healthcare Corp.
Market Cap
$104.07M
Net Profit Margin
-72.28%
TTM Avg
-61.99%
3Y Avg
-110.54%
5Y Avg
-40.29%
Market Cap
$106.23M
Net Profit Margin
-33.92%
TTM Avg
-11.74%
3Y Avg
-13.15%
5Y Avg
-11.88%
Market Cap
$100.37M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1167.97%
5Y Avg
-1200.09%
Market Cap
$108.39M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-1332.08%
Market Cap
$109.49M
Net Profit Margin
-14.78%
TTM Avg
-35.00%
3Y Avg
-39.46%
5Y Avg
-38.67%
Market Cap
$111.17M
Net Profit Margin
31.95%
TTM Avg
15.97%
3Y Avg
7.99%
5Y Avg
5.33%
Market Cap
$113.77M
Net Profit Margin
-270.22%
TTM Avg
-342.92%
3Y Avg
-204.73%
5Y Avg
-136.49%
Market Cap
$93.99M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definitive Healthcare Corp. (DH) | $104.07M | -72.28% | -61.99% | -110.54% | -40.29% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.23M | -33.92% | -11.74% | -13.15% | -11.88% |
| Anixa Biosciences, Inc. (ANIX)vs › | $100.37M | 0.00% | 0.00% | -1167.97% | -1200.09% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.39M | 0.00% | 0.00% | 0.00% | -1332.08% |
| Apyx Medical Corporation (APYX)vs › | $109.49M | -14.78% | -35.00% | -39.46% | -38.67% |
| Immunic, Inc. (IMUX)vs › | $109.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 31.95% | 15.97% | 7.99% | 5.33% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -270.22% | -342.92% | -204.73% | -136.49% |
| Biomea Fusion, Inc. (BMEA)vs › | $93.99M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-8.5%
Net Profit Margin
-72.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -9.82% |
| 2026-03-31 | -247.85% |
| 2025-12-31 | -15.14% |
| 2025-09-30 | -24.71% |
| 2025-06-30 | -12.43% |
| 2025-03-31 | -181.16% |
| 2024-12-31 | -94.84% |
| 2024-09-30 | -208.78% |
| 2024-06-30 | -335.18% |
| 2024-03-31 | -14.99% |
| 2023-12-31 | -15.52% |
| 2023-09-30 | -262.57% |
| 2023-06-30 | -14.05% |
| 2023-03-31 | -20.38% |
| 2022-12-31 | 16.28% |
| 2022-09-30 | -5.26% |
| 2022-06-30 | -10.06% |
| 2022-03-31 | -17.12% |
| 2021-12-31 | -22.86% |
| 2021-09-30 | -36.66% |
| 2021-09-17 | -37.77% |
| 2021-03-31 | -28.40% |
| 2020-12-31 | -47.13% |
| 2020-09-30 | -33.13% |
| 2020-06-30 | 46.41% |
| 2020-03-31 | -46.41% |
